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Introduction: Off-label use of psychotropic drugs is a common 
practice. In Colombia, no information is available in this regard. 
Objective: To describe off-label use of psychoactive drugs in a health 
promoting entity (EPS in Spanish) in Bogotá D.C.
Materials and methods: Cross sectional, observational study 
(prescription-indication), including a random sample of patients 
prescribed with psychotropic drugs between January and June 
2010. Sociodemographic, clinical, pharmacological and concordance 
variables were evaluated (correlation between use indication and 
approved indication). Multivariate analyzes were performed looking 
for an association with off-label prescriptions.
Results: 420 evaluated patients had a mean age of 44.2±18.8 
years, with female predominance (67.9%). Off-label prescription 
was found in 58.6-59.8% of cases. 84.3% of the prescriptions were 
delivered by general practitioners. The main psychoactive drugs 
prescribed for conditions such as tension headaches and insomnia 
were amitriptyline (n=128, 86.7% of off-label use), trazodone (n=93, 
88.2%) and fluoxetine (n=66, 36.4%). The multivariate analysis 
found that being a young adult (OR=1.99, 95%CI: 1.06-3.70; 
p=0.030), being treated by general medicine (OR=3.40, 95%CI: 1.50-
7.67; p=0.003) and being prescribed with amitriptyline (OR=11.38; 
95%CI: 5.06-25.58; p<0.001) or trazodone (OR = 13.08; 95%CI: 
5.23-32.68; p<0.001) increased the likelihood of receiving an off-
label prescription.
Conclusions: Psychotropic drugs in Bogotá are used, to a great extent, 
as off-label in indications other than those officially approved. Thus, it 
is important to strengthen education and control to achieve a rational, 
effective and safe use of drugs.
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| Resumen |
Introducción. El uso de psicofármacos por fuera de las indicaciones 
aprobadas (off-label) es una práctica común, de la cual no se tiene 
información en Colombia.
Objetivo. Describir el uso off-label de psicofármacos en una entidad 
promotora de salud de Bogotá D.C.
Materiales y métodos. Estudio observacional de prescripción-indicación 
con una muestra aleatoria de pacientes prescritos con psicofármacos 
entre enero y junio de 2010. Se evaluaron variables sociodemográficas, 
clínicas, farmacológicas y de concordancia y se realizaron análisis 
multivariados buscando asociación con prescripciones no aprobadas.
Resultados. Los 420 pacientes evaluados tenían una edad promedio 
de 44.2±18.8 años, con predominio femenino (67.9%). Se encontró 
prescripción no aprobada en 58.6-59.8% de los casos; el 84.3% de 
las formulas fueron hechas por medicina general. Los principales 
psicofármacos en indicaciones como cefalea tensional e insomnio 
fueron amitriptilina (n=128; 86.7% de uso no aprobado), trazodona 
(n=93; 88.2%) y fluoxetina (n=66; 36.4%). En el análisis multivariado 
se halló que ser un adulto joven (OR=1.99; IC95%: 1.06-3.70; p=0.030), 
ser tratado por medicina general (OR=3.40; IC95%: 1.50-7.67; p=0.003) 
y ser formulado con amitriptilina (OR=11.38; IC95%: 5.06-25.58; 
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p<0.001) o trazodona (OR=13.08; IC95%: 5.23-32.68; p<0.001) 
aumentan la probabilidad de recibir una prescripción no aprobada.
Conclusiones. En la aseguradora estudiada, los psicofármacos son 
utilizados en una importante proporción de indicaciones no aprobadas 
por las autoridades regulatorias, por lo cual es importante fortalecer 
la educación y el control para el empleo de los medicamentos de 
manera racional, efectiva y segura.
Palabras clave: Uso fuera de lo indicado; Psicotrópicos; 
Farmacoepidemiología; Colombia (DeCS).
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Introduction
Drugs used in medical practice are effective and safe in specific 
indications. This is achieved through a long and rigorous study 
process that provides information about the specific population that 
can be benefited, as well as the use and appropriate dose. However, 
off-label use of drugs is based on the ability or freedom of physicians 
who prescribe them beyond approved indications when a therapeutic 
alternative is required.
Recently, the consumption of psychoactive drugs has increased in 
Colombia, which is one of the drug groups with the highest proportion 
of non-approved use, particularly antidepressants, antipsychotics, 
anxiolytics and sedatives (2-7).
Use beyond approved indications is an issue, and there is no 
unanimity in this regard among regulatory agencies. In fact, many 
of them do not even have a clear position. The US Food and Drug 
Administration (FDA), for example, defines off- label as the “use 
for indication, dosage form, dose regimen, population or other use 
parameter not mentioned in the approved labeling” (8).
Formulations different from the approved indication, according to a 
systematic review by Carton et al. (9) based on studies conducted around 
the world, show that they represent 40-75% of the total prescriptions of 
psychotropic drugs, mainly for mood, anxiety, insomnia and agitation 
disorders. Quetiapine is revealed as the main drug used off-label, especially 
for anxiety and insomnia. The Colombian Food and Drug Surveillance 
Institute (Invima in Spanish) established through Act 38 of December 
13, 2006 (10) that “off-label” is a use different from that officially 
authorized by Invima”; therefore, it refers to unauthorized use and is 
“only acceptable if supported by clinical studies properly conducted.”
In Colombia, little information is known on the unauthorized use 
of medications, and there is no clear regulation on this issue. For 
this reason, the following prescription-indication study is presented 
(11) with the purpose of describing the use of psychoactive drugs 
beyond the guidelines approved by the regulatory agencies in a health 
promoting entity (EPS) of Bogota D.C. during the first half of 2010. 
It is also intended to suggest tools for the regulation and control of 
medications based on evidence of risk of adverse reactions, lack of 
effectiveness and inappropriate use of resources.
Materials and methods
Cross-sectional study in which prescription-indication information 
was collected retrospectively. The sample was obtained from the 
databases of drugs dispensed by Audifarma S.A. in an EPS of Bogota 
D.C., as well as from the medical records of the patients included.
From a universe of 16 912 patients prescribed with a psychotropic 
drug for at least one month between January and June 2010, a 
random sample of 385 patients was classified based on the drugs to 
be evaluated (expected prevalence: 50%, alpha level: 5%, power: 
80%) using the statistical package SPSS v22. Additionally, subjects 
with lower consumption requirements of diazepam, modafinil and 
zolpidem who were not included at first considering the classification 
criteria, were included later in the study, and, therefore, considered 
as mandatory, which increased the final size of the sample to 
420 individuals.
A list of patients was obtained based on the records of Audifarma 
S.A. These patients were given one or more of the following 
psychotropic drugs: valproic acid, alprazolam, amitriptyline, 
bromazepam, carbamazepine, chlorpromazine, clozapine, diazepam, 
divalproate, fluoxetine, gabapentin, haloperidol, lamotrigine, lithium, 
methylphenidate, midazolam, modafinil, olanzapine, oxcarbazepine, 
pregabalin, risperidone, sertraline, trazodone, venlafaxine and 
zolpidem. During the same period, a chemist reviewed the medical 
records to know the medical reason for the prescription. When the 
drugs with the highest amount of prescriptions were determined, 
a bibliographical search of the clinical and academic support 
was made for the different unapproved indications that were 
found (12).
For the study the following variables were taken into account, and 
were recorded in a Microsoft Excel database:
Sociodemographic: age (infants <14 years, adolescents 14-18 years, 
young adults 19-45 years, and adults >45 years) and sex.
Clinical: diagnosis and indication for prescription.
Pharmacological: name of prescribed medication, route of 
administration, posology, pharmaceutical form and specialty of the 
prescribing physician.
Concordance: correlation between the use indication of the 
psychoactive drug and the indication approved by Invima and FDA 
(indication, dose, route of administration, contraindications).
Finally, each prescription was classified as a) off-label: use other 
than the approved by the regulatory agency; b) approved use: use 
under approved conditions; c) no report: use is not specified in the 
medical record, and d) not evaluable: no information that supports the 
use of the psychoactive drug and impossibility to evaluate whether 
the prescription is appropriate or not (this option was only applied for 
mandatory inclusion drugs because of the impossibility of replacing 
the information).
This study met the specifications of the category “research 
without risk” according to Resolution 8430 of 1993 of the Ministry 
of Health of Colombia (13), which establishes the scientific, technical 
and administrative standards for health research. The principles 
of beneficence and confidentiality of patients were preserved as 
established by the Declaration of Helsinki.
Analysis plan
Data were analyzed using the statistical package SPSS Statistics 
version 22.0 for Windows (IBM, U.S.A). A description of 
frequencies and proportions was made for categorical variables, and 
central tendency and dispersion measures for continuous variables. 
Chi-square tests were used for comparing categorical variables, 
using a variable dependent on off-label use of a drug. Binary 
logistic regression models were used based on the prescription not 
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approved by Invima as a dependent variable (because it was of 
greater local interest), and p<0.05 was determined as the level of 
statistical significance.
Results
420 clinical histories of patients prescribed with psychoactive drugs 
in Bogotá D.C were evaluated. The mean age was 44.2±18.8, and 
distribution was obtained with a female predominance of 67.9%. 
Table 1 shows the distribution by sex, age group, specialty of the 
prescribing physician and method of use, as well as the proportion 
of off-label use.
Table 1. Socio-demographic variables, prescribing physician and off-label 
indications of psychoactive drugs in patients affiliated with a health 









Male 135 32.1 50.4 53.3
Female 285 67.9 62.5 62.8
Age group 
Infants (<14 years) 20 4.8 10.0 15.0
Adolescents (14-18 years) 35 8.3 48.6 45.7
Young adult (19-45 years) 179 42.6 69.8 70.9
Adult (>45 years) 186 44.3 54.8 56.5
Prescribing 
physician 
General practitioner 355 84.3 62.8 63.9
Neurology 15 3.6 40.0 40.0
Psychiatry 12 2.9 8.3 25.0
General results 
of use 
Off-label use 58.6 59.8
Approved use 31.0 29.8
No report 7.4 7.4
Not evaluable 3.1 3.1
Source: Own elaboration based on data obtained in the study.
It was not possible to describe the use of drugs by route of 
administration different from that recommended by the health agency, 
because 31.4% of prescriptions did not report this variable for each 
psychoactive drug. 
Table 2 lists the seven most frequent formulations of psychotropic 
drugs, and details the proportion of off-label prescriptions and the 
diagnostic reasons for off-label use. 
Bivariate analysis
When comparing the dependent variable “off-label prescription not 
approved by Invima”, the variables prescribing a psychoactive drug 
as a painkiller and being treated for headache with psychoactive drugs 
were found to be the most likely reasons for off-label indications. 
However, other variables such as prescription of amitriptyline or 
trazodone, receiving psychotropic drugs for migraine, being a young 
adult, and being formulated by general practitioners increased the 
probability of off-label prescriptions. Interestingly, the total number 
of patients treated for pain management (p=0.0001) and insomnia 
(p=0.0001) with psychotropic drugs were prescribed with drugs based 
on off-label indications.
It was also found that the use of psychoactive drugs for the treatment 
of epilepsy and being treated by psychiatry were the variables that 
further reduced the risk of unapproved use, although, prescription with 
fluoxetine or carbamazepine, depression and schizophrenia, being 
male and being an infant were associated with a lower probability 
of using psychoactive drugs with an off-label indication. 
Table 3 presents the associated variables in relation to the decrease 
or increase of the risk of prescribing off-label indications of drugs. 
Table 2. Psychopharmaceuticals most commonly used in off-label indica-
























































Invima: Food and Drug Surveillance Institute; FDA:  Food and Drug 
Administration.  
Source: Own elaboration based on data obtained in the study.
Table 3. Bivariate analysis of the variables associated with off-label pres-
cription of psychotropic drugs in patients affiliated with a health promoting 
entity. Bogotá D.C. 2010.
Associated variable OR 95%CI p
Protective 
factors of use 
in approved 
indication 
Being treated by psychiatry 0.06 0.08-0.47 <0.001
Treatment with fluoxetine 0.34 0.19-0.58 <0.001
Treatment with carbamazepine 0.12 0.04-0.33 <0.001
Being used for epilepsy 0.02 0.006-0.09 <0.001
Being used for depression 0.22 0.13-0.38 <0.001
Being used for schizophrenia 0.22 0.13-0.38 <0.001
Risk factors 
of use in 
approved 
indication 
Treatment with amitriptyline 7.59 4.33-13.29 <0.001
Treatment with trazodone 7.40 3.80-14.41 <0.001




Being used for headaches 23.6 5.67-98.36 <0.001
Being used for migraine 6.44 1.91-21.71 0.001
Adult (19-45 years) 2.29 1.52-3.44 <0.001
Being treated by a general 
practitioner
3.08 1.77-5.35 <0.001
Source: Own elaboration based on data obtained in the study.
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Multivariate analysis
By including the associated variables in a statistically significant 
manner, a binary logistic regression was performed. It is presented in 
Table 4, with the variables that were statistically associated with a higher 
risk of off-label prescriptions according to the approval of Invima.
Table 4. Multivariate analysis of the variables associated with off-label prescription of psychotropic drugs in patients affiliated with a health promoting 
entity. Bogotá D.C. 2010.
Variables B SE Wald DF Sig OR
95%CI
Lower Higher
Young adult 0.688 0.317 4.717 1.000 0.030 1.990 1.069 3.703
Being treated by a general 
practitioner
1.224 0.415 8.682 1.000 0.003 3.401 1.507 7.677
Treatment with 
amitriptyline
2.432 0.413 34.611 1.000 <0.001 11.380 5.062 25.585
Treatment with trazodone 2.571 0.467 30.276 1.000 <0.001 13.080 5.234 32.685
Headache 2.057 0.851 5.848 1.000 0.016 7.823 1.477 41.446
Epilepsy -2.720 0.829 10.765 1.000 0.001 0.066 0.013 0.334
Depression -1.743 0.383 20.674 1.000 <0.001 0.175 0.083 0.371
B: Regression coefficient; SE: standard error; DF: degree of freedom; Sig: level of significance.  
Source: Own elaboration based on data obtained in the study.
Discussion
This study served to identify the most common use of psychoactive 
drugs used beyond the approval of regulatory agencies and the FDA, 
as well as the diagnostic reasons, the prescriptive specialty and the 
variables associated with this practice in an EPS of Bogotá D.C. 
This contribution is the first approach to information regarding the 
unapproved use of psychotropic drugs in Colombia.
The proportion of psychoactive drugs found in this study (58.6%), 
especially antidepressants in non-approved indications, is within the 
range published by other authors such as Kharadi et al. (14) (39.5%, 
predominantly benzodiazepines), Leslie et al. (7) (60.2%) and Chen 
et al. (15) (75.4% predominantly antidepressants).
As presented in the systematic review of Carton et al. (9), off-
label prescriptions correspond to 40-75% of total prescriptions of 
psychotropic drugs worldwide according to the reviewed studies, 
which coincides with the data presented in this study. In this review, 
the most frequent uses of off-label medications are mood, anxiety 
and insomnia disorders. However, this research showed that they 
were almost always used for the management of tension headache 
and insomnia, being amitriptyline and trazodone the most used drugs, 
compared with quetiapine as the main drug in this systematic review 
(9). These differences may be explained by the access to medicines 
in the Colombian health system, where the prescription of many of 
these psychotropic drugs is restricted, although amitriptyline and 
trazodone are over-the-counter.
Off-label drug use may be justified in cases that require therapeutic 
alternatives, for example, in population groups with few investigations 
such as infants or pregnant women (1). However, statistical analyzes 
show that these prescriptions were more frequent in young adults, 
which may be related to the lack of knowledge by the general 
practitioner of the indications authorized for the drugs, the population 
that uses these type of drugs, and those easily related to diagnoses 
with other approved alternatives (1,2,8). 
This scenario leads to reflect on whether the physician, when 
prescribing, makes an appropriate analysis of the risk-benefit balance 
based on available clinical evidence and on the Invima guidelines that 
establish that unauthorized use is acceptable only if it is supported 
by adequate clinical studies (10).
Amitriptyline and trazodone were frequently prescribed off-label 
to treat tension headache and insomnia. Regarding amitriptyline, 
some studies have reported its effectiveness in these two indications 
(14-17); however, regulatory agencies still do not approve these uses. 
Something similar occurs with trazodone when indicated to treat 
sleep disorders. Some reports show good results, but it has not been 
approved for it yet. 
This situation creates a gap between the clinical practice guidelines 
that include it, and the surveillance and regulation measures that have 
not been updated. As a consequence, the responsibility of prescribing 
falls directly on physicians without the support of the drug regulatory 
agencies (17,18).
Amitriptyline, trazodone, fluoxetine, carbamazepine and valproic 
acid are less likely to be used without following the guidelines in 
patients with depression or epilepsy, but may increase the likelihood 
of unapproved use in different indications, although they may be 
effective (16,18). 
Given the results presented in this paper, questions are raised about 
the relevance of unapproved prescriptions, since the panorama of off-
label drug use does not offer conclusive answers. Perhaps, the best 
approach to a more rational use of drugs is based on the availability 
of resources —drugs and other technologies—, the robustness and 
availability of scientific evidence, the expertise of the physician, and 
the competence of the surveillance authorities (1). 
Therefore, the efforts of all health professionals, regulatory 
agencies and the pharmaceutical industry should be focused on 
working together to ensure patient safety, the collection of scientific 
evidence and an informed prescription. This translates into a more 
rational use of drugs (16,17).
One of the limitations of this work is its results, which were 
obtained from a single health promoting institution and can be 
extrapolated to populations with similar characteristics. In addition, 
the information was collected from the clinical records and the drug 
dispensing database, but not through interviews with physicians who 
are the actual decision makers and are responsible of selecting the 
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most appropriate therapy for their patients. However, the rigor of data 
collection allows us approach the reality of the use of psychoactive 
drugs in indications not authorized by regulatory agencies.
In conclusion, psychoactive drugs, especially antidepressants and 
antiepileptics, are used in this cohort of patients in a high proportion 
in indications not approved by regulatory agencies such as Invima and 
FDA, and were mostly prescribed by general practitioners for treating 
headaches and insomnia. It is important to strengthen information 
and continuing education programs, as well as relevant updates of 
health records of some psychotropic drugs with precise indications 
that already have sufficient evidence. Similarly, surveillance and 
control strategies should be developed for these drugs or included in 
pharmacovigilance programs by regulatory agencies when their uses 
may compromise patient safety in order to minimize the risks related 
to incomplete or inadequate information that may lead to increased 
off-label use of medications (18). 
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